Sukumar Nagendran insider trades

Open-market stock purchases and sales by Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, Inc, from SEC Form 4 filings since Jun 20, 2016.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -50%.

Recent trades

DateStockTradeValue
Jul 10, 2026TSHA Taysha Gene Therapies, IncSold$1.2M
Jun 10, 2026SLDB Solid Biosciences IncBought (not open market)—
Apr 10, 2026TSHA Taysha Gene Therapies, IncSold$892K
Apr 10, 2026TSHA Taysha Gene Therapies, IncBought (not open market)—
Jan 26, 2026TSHA Taysha Gene Therapies, IncSold$124K
Jan 23, 2026TSHA Taysha Gene Therapies, IncSold$423K
Jan 12, 2026TSHA Taysha Gene Therapies, IncSold$942K
Jan 12, 2026TSHA Taysha Gene Therapies, IncBought (not open market)—
Jan 12, 2026TSHA Taysha Gene Therapies, IncBought (not open market)—
Jan 12, 2026TSHA Taysha Gene Therapies, IncBought (not open market)—
Jan 12, 2026TSHA Taysha Gene Therapies, IncBought (not open market)—
Dec 1, 2025TSHA Taysha Gene Therapies, IncSold$1.2M
Dec 1, 2025TSHA Taysha Gene Therapies, IncBought (not open market)—
Nov 28, 2025TSHA Taysha Gene Therapies, IncSold$523K
Nov 28, 2025TSHA Taysha Gene Therapies, IncBought (not open market)—
Nov 28, 2025TSHA Taysha Gene Therapies, IncBought (not open market)—

Companies traded

  • TSHA Taysha Gene Therapies, Inc: 2 buys, 9 sales, last Jul 10, 2026
  • SLDB Solid Biosciences Inc: other filings, last Jun 10, 2026
  • AVXS AveXis, Inc: 42 sales, last May 15, 2018

Get free alerts when Sukumar Nagendran files a new trade →